Reports Q1 revenue $106.0M, consensus $104.89M. The company said, “The FDA’s recently announced roadmap for reducing animal testing in preclinical studies further demonstrates the vast opportunities ahead for Biosimulation. Certara (CERT) is well positioned to support the continued adoption of Biosimulation by industry to gain important insights into new therapies. We continue to work closely with our customers as they explore new approaches to make the drug development process more efficient…Our first quarter performance reflected strong commercial execution from our team across software and services. Despite the challenges facing our customers in the biopharma industry, we are reiterating guidance for 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- CERT Upcoming Earnings Report: What to Expect?
- Certara price target raised to $18 from $15 at KeyBanc
- Certara’s Hold Rating: Balancing Short-term Resilience with Long-term Regulatory Opportunities
- Certara’s Balanced Outlook: Hold Rating Amid Mixed Signals of Growth and Risk
- Certara launches Non-Animal Navigator solution